Publications in collaboration with researchers from Hospital Clinic Barcelona (15)

2016

  1. Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study)

    Annals of Oncology, Vol. 27, pp. vi312

2011

  1. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: Efficacy and cardiac safety from the GEICAM/2004-05 study

    Annals of Oncology, Vol. 22, Núm. 12, pp. 2591-2596

  2. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: A Spanish group for research on sarcomas study

    Journal of Clinical Oncology, Vol. 29, Núm. 18, pp. 2528-2533

  3. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study

    Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 55, Núm. 6, pp. 680-687

2010

  1. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: A phase I-II study by the Spanish group for research on sarcomas

    Cancer, Vol. 116, Núm. 15, pp. 3692-3701

  2. Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer

    Anticancer Research, Vol. 30, Núm. 6, pp. 2255-2261

  3. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: A Spanish Group for Sarcoma Research (GEIS) Study

    Annals of Oncology, Vol. 21, Núm. 7, pp. 1552-1557

2009

  1. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: An open-label randomized phase II study of the Spanish group for research on sarcomas

    Journal of Clinical Oncology, Vol. 27, Núm. 11, pp. 1893-1898

2007

  1. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

    Lancet Oncology, Vol. 8, Núm. 3, pp. 219-225

2006

  1. Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: A GEIS study

    British Journal of Cancer, Vol. 94, Núm. 12, pp. 1797-1802

  2. Phase II trial of doxorubicin plus escalated high-dose ifosfamide in patients with advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)

    Sarcoma, Vol. 2006

2005

  1. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: A study by the spanish group for research on sarcomas

    Cancer, Vol. 104, Núm. 8, pp. 1706-1712

2004

  1. Salvage surgical resection after High-Dose Ifosfamide (HDIF) based regimens in Advanced Soft Tissue Sarcoma (ASTS): A potential positive selection bias - A study of the Spanish group for research on sarcomas (GEIS)

    Journal of Surgical Oncology, Vol. 88, Núm. 1, pp. 44-49

  2. Sequential Dose-Dense Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcomas: A Phase II Trial by the Spanish Group for Research on Sarcomas (GEIS)

    Cancer, Vol. 100, Núm. 7, pp. 1498-1506

2003

  1. Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: A Cooperative Study by the GEICAM Group

    Clinical Breast Cancer, Vol. 3, Núm. 6, pp. 399-404